首页> 外文期刊>生物医学与环境科学(英文版) >SARS Patients-derived Human Recombinant Antibodies to S and M Proteins Efficiently Neutralize SARS-Coronavirus Infectivity
【24h】

SARS Patients-derived Human Recombinant Antibodies to S and M Proteins Efficiently Neutralize SARS-Coronavirus Infectivity

机译:SARS患者衍生的S和M蛋白人类重组抗体可有效中和SARS冠状病毒的感染性

获取原文
获取原文并翻译 | 示例
       

摘要

Objective To develop a specific SARS virus-targeted antibody preparation for emergent prophylaxis and treatment of SARS virus infection. Methods By using phage display technology, we constructed a naive antibody library from convalescent SARS patient lymphocytes. To obtain the neutralizing antibody to SARS virus surface proteins, the library panning procedure was performed on purified SARS virions and the specific Fab antibody clones were enriched by four rounds of repeated panning procedure and screened by highthroughput selection. The selected Fab antibodies expressed in the periplasma of E. Coli were soluble and further purified and tested for their binding properties and antiviral function to SARS virus. The functional Fab antibodies were converted to full human IgG antibodies with recombinant baculovirus/insect cell systems and their neutralizing activities were further determined. Results After four rounds of the panning, a number of SARS-CoV virus-targeted human recombinant Fab antibodies were isolated from the SARS patient antibody library. Most of these were identified to recognize both natural and recombinant SARS spike (S) proteins, two Fab antibodies were specific for the virus membrane (M) protein, only one bound to SARS-CoV nucleocapsid protein. The SARS-CoV S and M protein-targeted Fab or IgG antibodies showed significant neutralizing activities in cytopathic effect (CPE) inhibition neutralization test, these antibodies were able to completely neutralize the SARS virus and protect the Vero cells from CPE after virus infection. However, the N protein-targeted Fab or IgG antibodies failed to neutralize the virus. In addition, the SARS N protein-targeted human Fab antibody reacted with the denatured N proteins, whereas none of the S and M protein specific neutralizing antibodies did. These results suggested that the S and M protein-specific neutralizing antibodies could recognize conformational epitopes which might be involved in the binding of virions to cellular receptors and the fusion activity of the virus.Conclusion The SARS-CoV spike protein and membrane proteins are able to elicite efficient neutralizing antibodies in SARS patients. The neutralizing antibodies we generated in this study may be more promising candidates for prophylaxis and treatment of SARS infection.
机译:目的开发一种针对SARS病毒的特异性抗体制剂,用于紧急预防和治疗SARS病毒感染。方法利用噬菌体展示技术,从恢复期SARS患者的淋巴细胞中构建幼稚抗体库。为了获得针对SARS病毒表面蛋白的中和抗体,对纯化的SARS病毒体进行文库淘选程序,并且通过四轮重复淘选程序来富集特定的Fab抗体克隆,并通过高通量筛选进行筛选。在大肠杆菌的周质中表达的选择的Fab抗体是可溶的,并进一步纯化并测试其对SARS病毒的结合特性和抗病毒功能。用重组杆状病毒/昆虫细胞系统将功能性Fab抗体转化为完整的人IgG抗体,并进一步测定其中和活性。结果经过四轮淘选后,从SARS患者抗体库中分离了许多靶向SARS-CoV病毒的人重组Fab抗体。这些中的大多数已被识别为可识别天然和重组SARS刺突(S)蛋白,两种Fab抗体对病毒膜(M)蛋白具有特异性,只有一种与SARS-CoV核​​衣壳蛋白结合。靶向SARS-CoV S和M蛋白的Fab或IgG抗体在细胞病变效应(CPE)抑制中和测试中显示出显着的中和活性,这些抗体能够完全中和SARS病毒并在病毒感染后保护Vero细胞免受CPE侵害。但是,靶向N蛋白的Fab或IgG抗体无法中和病毒。另外,靶向SARS N蛋白的人Fab抗体与变性的N蛋白反应,而S蛋白和M蛋白特异性中和抗体均未反应。这些结果表明,S和M蛋白特异性中和抗体可以识别构象表位,这些构象表位可能与病毒体与细胞受体的结合以及病毒的融合活性有关。结论SARS-CoV穗蛋白和膜蛋白能够在SARS患者中引起有效的中和抗体。我们在这项研究中产生的中和抗体可能是预防和治疗SARS感染的更有希望的候选者。

著录项

  • 来源
    《生物医学与环境科学(英文版)》 |2005年第6期|363-374|共12页
  • 作者单位

    State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention;

    State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention;

    State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention;

    State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention;

    State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention;

    State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention;

    State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention;

    State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention;

    State Key Laboratory for Molecular Virology, Chinese Center for Disease Control and Prevention, 100 Yingxin Street, Xuanwu District, Beijing 100052, China;

    State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention;

    State Key Laboratory for Molecular Virology, Chinese Center for Disease Control and Prevention, 100 Yingxin Street, Xuanwu District, Beijing 100052, China;

    State Key Laboratory for Molecular Virology, Chinese Center for Disease Control and Prevention, 100 Yingxin Street, Xuanwu District, Beijing 100052, China;

    State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 内科学;
  • 关键词

    SARS-CoV; Phage display; Human antibody;

    机译:SARS-CoV;噬菌体展示;人类抗体;
  • 入库时间 2022-08-19 02:26:08
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号